Navigation Links
Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD
Date:11/7/2011

I 201335, BI 207127 and RBV showed high virologic response rates through week 12 across treatment arms. Viral suppression also was observed in the RBV-sparing arm but was lower than in the other arms at week 12.

  • 76 percent of patients who received BI 201335 once daily (QD) plus BI 207127 twice daily (BID) with RBV achieved viral response through week 12.
  • 70 percent of patients who received BI 201335 QD plus BI 207127 three times daily (TID) with RBV achieved viral response through week 12.
  • 57 percent of patients who received BI 201335 QD plus BI 207127 TID without RBV achieved viral response through week 12.

Breakthrough occurred in 13 percent of patients in BI 201335 plus BI 207127 TID with RBV treatment groups (arms one – three) and in 21 percent of patients in the BI 201335 plus BI 207127 BID with RBV treatment group. Breakthrough occurred in 15 percent of patients in the group that did not receive RBV.

The most frequent adverse events (AEs) were asthenia, pruritus, rash, photosensitivity, jaundice, nausea, vomiting and diarrhea. Across all treatment groups, 6–12 percent of patients discontinued due to AEs.

Results from this open-label, randomized, Phase 2b study were presented as a late-breaking poster titled, "Virologic Response to an Interferon-Free Regimen of BI 201335 and BI 207127, with and Without Ribavirin, in Treatment-Naive Patients with Chronic Genotype-1 HCV Infection: Week 12 Interim Results of the SOUND-C2 Study," by Stefan Zeuzem. In the study, 362 treatment-naive GT1 HCV patients were randomized to receive either:

  • BI 201335 120 mg QD plus BI 207127 600 mg TID plus RBV for 16 weeks;
  • BI 201335 120 mg QD plus BI 207127 600 mg TID plus RBV for 28 weeks;
  • BI 201335 120 mg QD plus BI 207127 600 mg TID plus RBV for 40 weeks;
  • BI 201335 120 mg QD plus BI 207127 600 mg BID plus RBV f
    '/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
2. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
3. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
4. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
5. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
6. Hepatitis C Phase 2A Trial Positive Results
7. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
8. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
9. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
10. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
11. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 22, 2014  New data demonstrates that ... most common form of female sexual dysfunction, Hypoactive Sexual ... or driving performance in premenopausal women when taken at ... Society of North America,s (SMSNA) ... . SMSNA accepted this study ...
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired ... nine months and the 3 rd quarter sales ended ... income was $448,000 for the nine months ended September 2014 ... "Even though our 3 rd quarter is usually a ... extends from July into September for many countries worldwide, we ...
(Date:11/21/2014)... Md. , Nov. 21, 2014  The University ... will host the ceremonial groundbreaking of the new A. ... Park. The new building will cultivate transformative new engineering ... Taking place at 10:00 a.m. on November ... the Paint Branch Parking Lot, adjacent to the Jeong ...
Breaking Medicine Technology:Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4
(Date:11/22/2014)... 22, 2014 A petition seeking a ... ) in minimally-invasive hysterectomies and fibroid removal surgeries ... end of October, Bernstein Liebhard LLP reports. According ... of November 21st, 2014. That represents an increase of ... signed on to the campaign.* , The campaign to ...
(Date:11/22/2014)... month has been a historical time for Angeldress.co.uk, an excellent ... from some renowned review websites. Recently, the company has added ... selection of wonderful sexy wedding dresses to its website. At ... up to an 80% discount on any order over GBP ... suitable dress at Angeldress.co.uk, which has garnered a hard core ...
(Date:11/22/2014)... CO (PRWEB) November 22, 2014 ... growth equity investments in the consumer brand sector, ... The investment will be used to help fund ... product pipeline rollout, particularly its proprietary apparel and ... will join BackJoy’s Board of Directors. , BackJoy ...
(Date:11/22/2014)... A Xarelto lawsuit has been filed on ... $10 million in damages from the makers and marketers of ... lawsuit, the woman began using Xarelto in March 2012 and ... lawsuit she suffered life-threatening bleeding in July 2012 and as ... and emotional distress. The lawsuit purports that the woman’s injuries ...
(Date:11/22/2014)... The widely used heart drug digoxin is associated with ... have the heart rhythm disorder atrial fibrillation but no ... Atrial fibrillation is a common form of irregular heartbeat ... for stroke among older Americans. Digoxin has been used ... heartbeat, the authors of the new study said, and ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 3
... China has announced fresh measures to ensure substandard drugs ... salvage its credibility following a raft of safety scandals, ... food and drug watchdog will have to abide by ... of medicines and curb corruption within the industry, the ...
... issue of The Journal of the American Dental Association ... restoration now can help eliminate bacteria in root ... Austria, credits the development of miniaturized, flexible fiber tips ... (root canal) treatment. ,Dr. Ulrich Schoop and ...
... duties and caring for elderly parents, Canadians can now turn ... gramps and granny. ,"It is really meant ... now are typically (comprised of) Baby Boomers who have children ... two groups," said Victoria Sopik, president of Kids and Company. ...
... hundred seats in the medical colleges of the Philippines ... especially India and China. ,It will cost ... million to study in a Philippine university. The amount ... ,The government of Philippines has set aside ...
... in man and his best friend is an increase in the ... might be able to tell us why and how certain cancers ... canine and human cancer patients. , ,An expert ... London that studying tumours in dogs and humans could give us ...
... scientists lead by Professor Nick Harberd have discovered how ... climate and environment. ,Plants adapt their ... as germination and flowering, to take advantage of ... environment is not favourable. This involves many complex signalling ...
Cached Medicine News:Health News:Laser to Fight Root Canal Bacteria 2Health News:Canada Daycare Looks After Elderly Parents While Children Work 2Health News:Cancer Cures for Canines 2Health News:Plants Respond to Changing Environment 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: